BioCentury | Sep 12, 2019
Distillery Therapeutics

CDK11B as a new cancer target

...cancer target (see "Cold Spring Harbor Team Finds Off-target Activity Can Drive Antitumor Effects" ). OncoTherapy Science Inc....
BioCentury | Sep 11, 2019
Translation in Brief

Cold Spring Harbor team finds off-target activity can drive antitumor effects

...assays to clarify the mechanism of one of the compounds, preclinical TOPK inhibitor OTS964 from OncoTherapy Science Inc....
...cancer vaccine PVX-410 from OncoPep Inc. is in Phase I testing for smoldering multiple myeloma. OncoTherapy...
...Histone deacetylase 6; TOPK (PBK) - PDZ binding kinase Sandi Wong, Staff Writer Cold Spring Harbor Laboratory OncoTherapy Science Inc. CRISPR RNAi OTS964...
BioCentury | Mar 26, 2018
Translation in Brief

Tagging out

...did not impair proliferation of a breast cancer cell line, calling the target into question. OncoTherapy Science Inc....
BioCentury | Dec 7, 2016
Clinical News

GNS identifies disease drivers from CoMMpass data

...Ltd. (Tokyo:4502) and Johnson & Johnson (NYSE:JNJ) market Velcade. GNS said MELK inhibitor OTS167 from OncoTherapy Science Inc....
BioCentury | Jan 5, 2015
Finance

4Q14 Stock Wrap-up: Grow early, grow often

...of the HBV genome conjugated to N-acetylgalactosamine-polymer and cholesterol ligands. In the $200-$499 million group, OncoTherapy Science Inc....
...Calif. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Nymox Pharmaceutical Corp. (NASDAQ:NYMX), Saint-Laurent, Quebec OncoTherapy Science Inc....
BioCentury | Nov 20, 2014
Cover Story

Tapping TOPK

...hematopoietic cells and increases its therapeutic index. 1 The inhibitor was developed by Japanese biotech OncoTherapy Science Inc....
...cells could eliminate some of the risks associated with other cytokinesis enzymes. In 2011, the OncoTherapy...
...formulation for studies in solid cancers and plan for it to be ready by YE15. OncoTherapy...
BioCentury | Nov 13, 2014
Distillery Therapeutics

Indication: Cancer

...temporary leukocytopenia and no body weight loss. Ongoing work includes GMP manufacturing of OTS964 by OncoTherapy Science Inc....
...acute myeloid leukemia. SciBX 7(44); doi:10.1038/scibx.2014.1286 Published online Nov. 13, 2014 Patent application filed by OncoTherapy...
BioCentury | Apr 1, 2013
Finance

1Q Stock Wrap-Up: Out fast at opening bell

...forecast. Vivus launched the obesity drug in September. Japanese cancer companies NanoCarrier Co. Ltd. and OncoTherapy Science Inc....
...of 1,569.19 (see BioCentury, Feb. 11) . NanoCarrier was up 281% for the quarter, while OncoTherapy...
...is partnered with Nippon Kayaku Co. Ltd. , is in Phase III for breast cancer. OncoTherapy's...
BioCentury | Feb 11, 2013
Finance

Bubbling up in Japan

...Tokyo:2370) ¥28,810 ¥8,480-¥46,300 56% 79% $228.0 NanoCarrier Co. Ltd. (Tokyo:4571) ¥278,300 ¥28,300-¥480,000 308% 173% $863.4 OncoTherapy Science Inc....
BioCentury | Apr 9, 2012
Company News

OncoTherapy, Shionogi deal

...Shionogi and OncoTherapy expanded a February 2009 deal granting the pharma exclusive, worldwide rights to develop...
...vaccines from OncoTherapy to include all peptide vaccines discovered by the biotech for all indications. OncoTherapy...
...and is eligible for milestones, plus royalties. Under the 2009 deal, Shionogi had rights to OncoTherapy's...
Items per page:
1 - 10 of 16
BioCentury | Sep 12, 2019
Distillery Therapeutics

CDK11B as a new cancer target

...cancer target (see "Cold Spring Harbor Team Finds Off-target Activity Can Drive Antitumor Effects" ). OncoTherapy Science Inc....
BioCentury | Sep 11, 2019
Translation in Brief

Cold Spring Harbor team finds off-target activity can drive antitumor effects

...assays to clarify the mechanism of one of the compounds, preclinical TOPK inhibitor OTS964 from OncoTherapy Science Inc....
...cancer vaccine PVX-410 from OncoPep Inc. is in Phase I testing for smoldering multiple myeloma. OncoTherapy...
...Histone deacetylase 6; TOPK (PBK) - PDZ binding kinase Sandi Wong, Staff Writer Cold Spring Harbor Laboratory OncoTherapy Science Inc. CRISPR RNAi OTS964...
BioCentury | Mar 26, 2018
Translation in Brief

Tagging out

...did not impair proliferation of a breast cancer cell line, calling the target into question. OncoTherapy Science Inc....
BioCentury | Dec 7, 2016
Clinical News

GNS identifies disease drivers from CoMMpass data

...Ltd. (Tokyo:4502) and Johnson & Johnson (NYSE:JNJ) market Velcade. GNS said MELK inhibitor OTS167 from OncoTherapy Science Inc....
BioCentury | Jan 5, 2015
Finance

4Q14 Stock Wrap-up: Grow early, grow often

...of the HBV genome conjugated to N-acetylgalactosamine-polymer and cholesterol ligands. In the $200-$499 million group, OncoTherapy Science Inc....
...Calif. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Nymox Pharmaceutical Corp. (NASDAQ:NYMX), Saint-Laurent, Quebec OncoTherapy Science Inc....
BioCentury | Nov 20, 2014
Cover Story

Tapping TOPK

...hematopoietic cells and increases its therapeutic index. 1 The inhibitor was developed by Japanese biotech OncoTherapy Science Inc....
...cells could eliminate some of the risks associated with other cytokinesis enzymes. In 2011, the OncoTherapy...
...formulation for studies in solid cancers and plan for it to be ready by YE15. OncoTherapy...
BioCentury | Nov 13, 2014
Distillery Therapeutics

Indication: Cancer

...temporary leukocytopenia and no body weight loss. Ongoing work includes GMP manufacturing of OTS964 by OncoTherapy Science Inc....
...acute myeloid leukemia. SciBX 7(44); doi:10.1038/scibx.2014.1286 Published online Nov. 13, 2014 Patent application filed by OncoTherapy...
BioCentury | Apr 1, 2013
Finance

1Q Stock Wrap-Up: Out fast at opening bell

...forecast. Vivus launched the obesity drug in September. Japanese cancer companies NanoCarrier Co. Ltd. and OncoTherapy Science Inc....
...of 1,569.19 (see BioCentury, Feb. 11) . NanoCarrier was up 281% for the quarter, while OncoTherapy...
...is partnered with Nippon Kayaku Co. Ltd. , is in Phase III for breast cancer. OncoTherapy's...
BioCentury | Feb 11, 2013
Finance

Bubbling up in Japan

...Tokyo:2370) ¥28,810 ¥8,480-¥46,300 56% 79% $228.0 NanoCarrier Co. Ltd. (Tokyo:4571) ¥278,300 ¥28,300-¥480,000 308% 173% $863.4 OncoTherapy Science Inc....
BioCentury | Apr 9, 2012
Company News

OncoTherapy, Shionogi deal

...Shionogi and OncoTherapy expanded a February 2009 deal granting the pharma exclusive, worldwide rights to develop...
...vaccines from OncoTherapy to include all peptide vaccines discovered by the biotech for all indications. OncoTherapy...
...and is eligible for milestones, plus royalties. Under the 2009 deal, Shionogi had rights to OncoTherapy's...
Items per page:
1 - 10 of 16